Amplia Therapeutics Limited (INNMF)
Sector: Biotechnology
Industry: Biotechnology
Amplia Therapeutics Limited
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 12, 2026 | 0.0535 | 0.0535 | 0.0535 | 0.0535 | 475 |
| Nov 11, 2026 | 0.0552 | 0.0634 | 0.0552 | 0.0634 | 6,080 |
| Nov 9, 2026 | 0.0696 | 0.0696 | 0.0578 | 0.0578 | 4,088 |
| Nov 5, 2026 | 0.0644 | 0.0644 | 0.0644 | 0.0644 | 1,750 |
| Nov 3, 2026 | 0.0587 | 0.0587 | 0.0587 | 0.0587 | 4,600 |
| Oct 28, 2026 | 0.0540 | 0.0540 | 0.0540 | 0.0540 | 6,000 |
| Oct 23, 2026 | 0.0550 | 0.0550 | 0.0550 | 0.0550 | 5,000 |
| Oct 19, 2026 | 0.0600 | 0.0600 | 0.0500 | 0.0529 | 57,250 |
| Oct 16, 2026 | 0.0540 | 0.0575 | 0.0515 | 0.0575 | 60,000 |
| Oct 14, 2026 | 0.0684 | 0.0776 | 0.0500 | 0.0750 | 66,000 |
| Oct 13, 2026 | 0.0635 | 0.0720 | 0.0501 | 0.0501 | 64,612 |
| Oct 12, 2026 | 0.0905 | 0.0905 | 0.0905 | 0.0905 | 120,000 |
| Oct 9, 2026 | 0.0800 | 0.0800 | 0.0713 | 0.0713 | 12,500 |
| Oct 7, 2026 | 0.0500 | 0.0771 | 0.0500 | 0.0700 | 22,412 |
| Oct 5, 2026 | 0.0700 | 0.0800 | 0.0700 | 0.0800 | 30,000 |
| Oct 2, 2026 | 0.0800 | 0.0800 | 0.0800 | 0.0800 | 35,000 |
Established in 2000 and headquartered in Melbourne, Australia, Amplia Therapeutics Limited is a pharmaceutical firm dedicated to the discovery and development of focal adhesion kinase (FAK) inhibitors.
The company's therapeutic endeavors are concentrated on oncology (cancer) and chronic fibrotic diseases.
Its drug development pipeline includes AMP945, a FAK inhibitor that has successfully completed Phase I clinical trials and is being explored for its efficacy in treating pancreatic cancer, idiopathic pulmonary fibrosis, and a broader spectrum of cancerous and fibrotic conditions. Another compound, AMP886, is also under development for potential applications in cancer and fibrotic disorders. Amplia Therapeutics maintains a strategic collaboration with the Garvan Institute of Medical Research in Sydney, and the company adopted its current name in September 2018, having previously operated as Innate Immunotherapeutics Limited.
based on 513.31M shares outstanding
30d Avg
10.65K
60d Avg
29.88K
90d Avg
27.44K
Amplia Therapeutics Limited (OTC: INNMF) traded at $0.0535 on Nov 12, 2026, down 15.56% from the previous close of $0.0634. 52-week range: $0.0500 to $0.2700. The company is in the Healthcare sector (Biotechnology).